Allogene reports promising results for CAR T therapy in lymphoma
SOUTH SAN FRANCISCO - Allogene Therapeutics, Inc. (NASDAQ:ALLO), a biotechnology firm specializing in allogeneic CAR T ...
Innovators gear up work on ‘green’ hydrogen plane with plans for nonstop 9-day trip ...
Swiss aviation pioneer Bertrand Piccard is developing a plane powered by liquid hydrogen after a much-hyped flight in 2015 ...
Cure Today7 小时
Breyanzi Improves Responses in R/R Indolent B-Cell Non-Hodgkin Lymphoma
Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...
Solid-State Batteries Are In ‘Trailblazer’ Mode. What's Holding Them Up?
“We’re in the mode of trailblazing the breakthroughs to move them closer to automotive applications,” Siyu Huang, the CEO of ...
BioSpace11 小时
Pfizer Continues Cancer Rally as Adectris Label Expands to Non-Hodgkin Lymphomas
Leaked data showed that Pfizer’s mevrometostat has strong therapeutic potential in metastatic castration-resistant prostate ...
‘It’s working!’ Columbus cancer center is first in Georgia to administer this new therapy
Susan Williams,seated center, a patient at the John B. Amos Cancer Center in Columbus, Georgia, is receiving a new cancer ...
GEN16 小时
TG Therapeutics Licenses Maxcyte Tech to Develop Cell Therapies for Autoimmune Disease
MaxCyte's technology will support TG Therapeutics' efforts to develop a CD19 CAR T cell therapy program for autoimmune diseases.
Cancer Therapy Advisor19 小时
Adcetris Combo Approved for Rel/Ref Large B-Cell Lymphoma
The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...